Dimenydrinate vs Ondansetron for PONV (DONV)

NCT ID: NCT05590936

Last Updated: 2022-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

190 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2022-12-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate the impact of dimenydrinate (H1-receptor antagonist) versus ondansetron (HT3-receptor antagonist) in postoperative nausea and vomiting, in surgery-related preoperative stress and in the incidence of postoperative complications that could lengthen the LOS in PACU and/or the overall LOS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dimenydrinate has been extensively used for motion sickness. However, as far as postoperative nausea and vomiting is concerned the results are still conflicting.

This study will investigate the impact of dimenydrinate (H1-receptor antagonist) versus ondansetron (HT3-receptor antagonist) in postoperative nausea and vomiting, in surgery-related preoperative stress and in the incidence of postoperative complications that could lengthen the LOS in PACU and/or the overall LOS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PONV in Laparoscopic Cholocystectomies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dimenydrinate

Preoperative per os administration of 50 mg dimenydrinate

Group Type ACTIVE_COMPARATOR

Dimenhydrinate Tablets

Intervention Type DRUG

2 hours preoperative per os administration of 50 mg dimenhydrinate

Ondasentron

Intraoperative intravenous administration of 4 mg ondansetron

Group Type OTHER

Ondansetron iv

Intervention Type DRUG

Intraoperative intravenous administration of 4 mg ondansetron

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dimenhydrinate Tablets

2 hours preoperative per os administration of 50 mg dimenhydrinate

Intervention Type DRUG

Ondansetron iv

Intraoperative intravenous administration of 4 mg ondansetron

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-75 years old
* ASA PS I-III
* Undergoing laparoscopic general surgery operations or laparoscopic gynecological operations

Exclusion Criteria

* Refused to participate
* Age other than 18-75 years old
* Pregnant patients
* Non-elective operations
* Patients that are not able to receive p.os agents
* Medical history of Brugada Sdr or Brugada-like/related ECG abnormalities
* Long-Qt Sdr or concurrent use of medications that may cause long-QT ECG abnormalities
* Medical or family history of psychosis
* Allergy in dimenydrinate or in dimenydrinate drug versions
* Perioperative use of dexamethasone
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Thessaly

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Elena Arnaoutoglou

Professor of anesthesiology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elena Arnaoutoglou, MD, PhD

Role: STUDY_CHAIR

University of Thessaly

Konstantinos George Stamoulis, MD, PhD

Role: STUDY_DIRECTOR

University Hospital of Larissa

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Larisa, Department of Anesthesiology

Larissa, Thessaly, Greece

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Greece

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

52699

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.